(Q49122617)

18 February 2018

title

Neurohumoural and Structural Changes in Schizophrenia: Two Dimensions of Pathology (English)

1 reference

10.1016/S0079-6123(08)64211-9

DOI

https://api.crossref.org/works/10.1016/S0079-6123(08)64211-9

11 August 2023

1 reference

T. J. Crow

1

1 reference

PubMed ID

6131479

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6131479

11 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

6131479

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6131479

11 August 2023

publication date

1 January 1982

1 reference

18 February 2018

Progress in Brain Research

published in

1 reference

18 February 2018

volume

55

1 reference

18 February 2018

page(s)

407-417

1 reference

18 February 2018

Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Schizophrenia: Schneider's first-rank symptoms and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Central dopamine turnover in schizophrenic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Definitions of schizophrenia: concordance and prediction of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

The activities of brain dopamine-?-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Viral causes of psychiatric disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Subjective Age in Chronic Schizophrenia: Evidence for a Sub-Group of Patients with Defective Learning Capacity?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Age disorientation in chronic schizophrenia: the nature of the cognitive deficit

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Intracranial self-stimulation with electrodes in the region of the locus coeruleus.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Characteristics of patients with schizophrenia or neurological disorder and virus-like agent in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Cognitive impairment associated with morphological brain abnormalities on computed tomography in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Cerebral ventricular size and neuropsychological impairment in young chronic schizophrenics. Measurement by the standardized Luria-Nebraska Neuropsychological Battery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

An Appraisal of the Continuing Practice of Prescribing Tranquillizing Drugs for Long-stay Psychiatric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Cerebral ventricular size and cognitive impairment in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

The dementia of dementia praecox.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Chlorpromazine and the untreated chronic schizophrenic: a long-term trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Brain neurotransmitter receptors after long-term haloperidol: Dopamine, acetylcholine, serotonin, α-noradrenergic and naloxone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Reduced monoamine oxidase activity in blood platelets from schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Increased dopamine-receptor sensitivity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

The disabilities of chronic schizophrenia--their nature and the factors contributing to their development.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Cerebrospinal Fluid Amine Metabolites in Acute Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Neurologic soft signs in schizophrenia and character disorders. Organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Stereotyped activities produced by amphetamine in several animal species and man

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Possible virus in schizophrenia and some neurological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Lateral Cerebral Ventricular Enlargement in Chronic Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Tritiated LSD Binding in Frontal Cortex in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

The nucleus accumbens–possible site of antipsychotic action of neuroleptic drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2964211-9

7 January 2021

Neurotransmitter receptors in brain in schizophrenia

series ordinal

44

1 reference

10.1016/S0079-6123(08)64211-9

DOI

https://api.crossref.org/works/10.1016/S0079-6123(08)64211-9

10.1016/S0079-6123(08)64211-9

11 August 2023

Identifiers

DOI

0 references

PubMed ID

6131479

1 reference

18 February 2018